What is HC Wainwright's Forecast for CNTX Q3 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Context Therapeutics in a research report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics' Q4 2025 earnings at ($0.05) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01.

A number of other brokerages also recently weighed in on CNTX. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st. JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price for the company. Finally, Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $6.17.

Remove Ads

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX traded down $0.05 during trading on Monday, hitting $0.74. The company's stock had a trading volume of 100,910 shares, compared to its average volume of 387,524. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75. The company has a market capitalization of $66.07 million, a PE ratio of -0.81 and a beta of 2.06. The stock's 50-day moving average price is $0.84 and its two-hundred day moving average price is $1.40.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently modified their holdings of CNTX. Shay Capital LLC acquired a new stake in Context Therapeutics in the 4th quarter valued at about $52,000. MPM Bioimpact LLC acquired a new position in Context Therapeutics during the fourth quarter worth about $15,441,000. Millennium Management LLC boosted its holdings in shares of Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after acquiring an additional 34,835 shares in the last quarter. Citadel Advisors LLC bought a new stake in Context Therapeutics during the 4th quarter worth approximately $31,000. Finally, Allostery Investments LP bought a new position in shares of Context Therapeutics during the fourth quarter worth about $998,000. Institutional investors and hedge funds own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.